Strayer D S, Merritt T A, Makunike C, Hallman M
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston 77030.
Am J Pathol. 1989 Apr;134(4):723-32.
The authors tested the antigenicity of human lung surfactant isolated from amniotic fluid. Mice and rabbits were immunized. Rabbit polyclonal antisera to these surfactant preparations were absorbed with normal human plasma proteins. Polyclonal antisera reacted with both high molecular weight (35 kd) surfactant apoprotein and to lower molecular weight species, both 18 kd and 9 kd. Mice were used to generate monoclonal antibodies to surfactant. Enzyme-linked immunosorbant assay was used to identify five monoclonal antibodies that reacted with surfactant. By Western blot analysis, all of these recognized a low molecular weight surfactant species (9 kd) that could be either SP-B or SP-C. One reacted with a 37 kd protein in the surfactant preparation, consistent with SP-A. One monoclonal antibody also recognized a higher molecular weight species (44 kd) of unknown origin. The ability of antisera and monoclonal antibodies to inhibit the functional activity of surfactant was assayed using a pulsating bubble surfactometer. Rabbit polyclonal antisera inhibited initial surface adsorption to equilibrium surface tension and increased the minimum surface tension after 1 and 5 minutes of initiation of pulsations. This inhibitory activity of the antisera was noted in divalent F(ab')2 fragments. Monovalent F(ab) fragments and control normal rabbit sera did not inhibit surfactant function in this assay. Of the anti-surfactant monoclonal antibodies that reacted with surfactant by ELISA and Western blot, three inhibited its capacity to lower surface tension on the pulsating bubble apparatus. The other two monoclonal antibodies showed no functional inhibitory activity. It is concluded that both the 35 kd SP-A and the 9 kd proteins of human surfactant are highly immunogenic and partially crossreactive. Resulting antibodies could alter the ability of surfactant to perform its physiologic function, ie, to lower surface tension.
作者检测了从羊水分离出的人肺表面活性物质的抗原性。对小鼠和兔子进行免疫。兔抗这些表面活性物质制剂的多克隆抗血清用正常人血浆蛋白进行吸收。多克隆抗血清与高分子量(35kd)表面活性物质载脂蛋白以及较低分子量的物质(18kd和9kd)均发生反应。利用小鼠产生针对表面活性物质的单克隆抗体。采用酶联免疫吸附测定法鉴定出五种与表面活性物质发生反应的单克隆抗体。通过蛋白质印迹分析,所有这些抗体均识别出一种低分子量的表面活性物质(9kd),其可能是表面活性蛋白B或表面活性蛋白C。有一种抗体与表面活性物质制剂中的一种37kd蛋白发生反应,与表面活性蛋白A一致。一种单克隆抗体还识别出一种来源不明的较高分子量物质(44kd)。使用脉动气泡表面张力仪检测抗血清和单克隆抗体抑制表面活性物质功能活性的能力。兔多克隆抗血清抑制初始表面吸附至平衡表面张力,并在脉动开始1分钟和5分钟后增加最小表面张力。抗血清的这种抑制活性在二价F(ab')2片段中也有体现。单价F(ab)片段和对照正常兔血清在该测定中不抑制表面活性物质的功能。在通过酶联免疫吸附测定法和蛋白质印迹法与表面活性物质发生反应的抗表面活性物质单克隆抗体中,三种抑制了其在脉动气泡装置上降低表面张力 的能力。另外两种单克隆抗体未显示出功能抑制活性。得出的结论是,人表面活性物质的35kd表面活性蛋白A和9kd蛋白均具有高度免疫原性且存在部分交叉反应性。产生的抗体可能会改变表面活性物质执行其生理功能(即降低表面张力)的能力。